JP2009196931A - Antiobestic agent and food and drink using the same - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an antiobestic agent expected to achieve obesity-inhibiting effects, especially the effects for inhibiting the obesity caused by the accumulation of the subcutaneous fat, and to provide a food and drink using the agent. <P>SOLUTION: The antiobestic agent contains pinitol as an active ingredient. The food and drink contains the antiobestic agent. <P>COPYRIGHT: (C)2009,JPO&INPIT

Description

  The present invention relates to an anti-obesity agent and a food and drink using the same, which are expected to have an obesity-inhibiting effect, particularly an effect of suppressing the accumulation of subcutaneous fat.

  In recent years, the number of obese people has increased rapidly due to high calories and lack of exercise in the diet, which has become a social problem. Obesity usually results from the accumulation of excess energy as fat that occurs when the energy consumed exceeds the energy consumed. The fat accumulated in this way is roughly classified into subcutaneous fat and visceral fat. Of these, subcutaneous fat is difficult to reduce once accumulated compared to visceral fat. Such obesity problems are observed not only in humans but also in animals such as pets and livestock.

  The methods for relieving obesity generally include exercises to promote energy consumption and fat burning, diets that restrict intake of fat and sugar and overall diet, and use of drugs such as appetite suppressants. Has been done.

  However, consumption of subcutaneous fat due to exercise requires time and labor, and is difficult to perform continuously in a busy social life. In addition, the diet therapy as described above is extremely difficult to execute in daily life because excessive stress is applied due to the limitation of the amount of meal. Moreover, if you take the wrong diet, it may be harmful to your health. In addition, the elimination of obesity due to the use of drugs often causes side effects and is too dangerous for use to eliminate mild obesity and prevent obesity.

  The present invention has been made in view of such circumstances, and an anti-obesity agent that can be expected to have an obesity-inhibiting effect, in particular, an obesity-inhibiting effect caused by the accumulation of subcutaneous fat, without causing side effects, and the same are used. The purpose is to provide food and drink.

  In order to achieve the above object, the present invention has as a first summary an anti-obesity agent containing pinitol as an active ingredient, and as a second summary of foods and drinks containing the anti-obesity agent.

  That is, the present inventors have intensively studied to solve the above problems. In the course of that research, we focused on inositol, which has been reported for various physiological effects. Inositol has stereoisomers such as myo-inositol, D-kilo-inositol, scyllo-inositol, L-kilo-inositol, neo-inositol, etc. Research has been conducted on the use of such as those showing an improvement effect (for example, JP-A-7-223939, International Publication No. 1990/010439, JP-A-4-505218, JP-A-11-502223). Issue gazette). As a result of further research on such inositol, the present inventors have caused side effects when pinitol (3-O-methyl-D-kilo-inositol), which is a kind of inositol, is used as an active ingredient. In addition, the present inventors have found that a very significant obesity-suppressing effect, particularly an obesity-suppressing effect caused by the accumulation of subcutaneous fat, has been found by experiments and have reached the present invention.

  As described above, the antiobesity agent of the present invention contains pinitol as an active ingredient. And by taking it (especially by taking the daily intake of pinitol in a specific range), it effectively suppresses obesity and effectively deposits subcutaneous fat without showing any side effects. Can be suppressed.

  And when it is set as the food / beverage products containing the said anti-obesity agent, the obesity suppression effect comes to be obtained by continuing eating / drinking this like a normal food / beverage product.

  Next, embodiments of the present invention will be described in detail.

  The anti-obesity agent of the present invention contains pinitol as an active ingredient.

  Pinitol (3-O-methyl-D-chiro-inositol) is a methoxy group in which the hydroxyl group at the 3-position of D-chiro-inositol is methylated.

  Pinitol is prepared by chemical synthesis, even if it is purified and extracted from a composition possessed or produced by a living organism that exists in nature. It may be obtained by a scientific method.

  Pinitol is abundant in plants such as locust bean, soybean, pine, clover, lotus root, carnation, bougainvillea and the like. In addition to the seeds of these plants, stems and leaves are also rich in pinitol. As a method for extracting pinitol from these plants, for example, the plant is immersed in a high-temperature extraction solvent. As the extraction solvent, water, a water-soluble solvent such as methanol, ethanol, isopropanol, n-propanol, and acetone, or a water-soluble solvent is used. Moreover, it is preferable from the point of extraction efficiency that the extraction temperature by the said extraction solvent is 50-100 degreeC. Furthermore, in the extraction method, the extraction medium may be refluxed for extraction.

  And the target pinitol can be obtained by drying, concentrating, refine | purifying, etc. about the extract obtained in this way.

  The anti-obesity agent of the present invention contains pinitol obtained as described above as an active ingredient. From the viewpoint of its effectiveness, the pinitol content is preferably in the range of 0.01 to 100% by weight. Is. In order to obtain the anti-obesity agent of the present invention, the extract may be used directly as it is, but in general, the extract is dissolved or dispersed in an appropriate liquid carrier, or an appropriate powder. The one mixed with the carrier is used.

  Examples of pharmacologically acceptable carriers include excipients, lubricants, binders and disintegrants in solid formulations, or solvents, solubilizers, suspending agents, isotonic agents, buffers in liquid formulations. And soothing agents.

  In addition, for preparation of the anti-obesity agent of the present invention, various components usually used for preparation are optionally used. Examples thereof include starch, dextrin, lactose, corn starch, inorganic salts and the like. It is done.

  Examples of dosage forms for providing the anti-obesity agent of the present invention as pharmaceuticals or supplements include ampoules, tablets, capsules, granules, fine granules, powders, infusions, and drinks.

  And it is preferable to set the amount of the antiobesity agent of the present invention so that the daily intake of pinitol is in the range of 10 to 1200 mg from the viewpoint of its effectiveness.

  Furthermore, the anti-obesity agent of the present invention can also be provided as a form in which it is involved in food and drink. Examples of the foods and drinks include health foods (tablets, powders, granules, concentrated liquids), soft drinks, foods for specified health use, drinks, tea, milk, pudding, jelly, rice cake, gum, yogurt, chocolate, soup, cookies , Snacks, wine, shochu, sake, dressing, boiled beans, tofu, natto, soy milk, roasted beans, dried beans, miso, etc. And the obesity suppression effect comes to be obtained by eating and drinking these food and drink similarly to normal food and drink. In addition, since pinitol has a unique sweetness, the above-mentioned food / beverage products can be sweetened without substantially containing a caloric sweetener that can cause obesity such as sucrose, fructose, and glucose. There is also.

  The anti-obesity agent of the present invention can obtain an obesity-suppressing effect not only in humans but also in animals such as pets and livestock, and the dosage is different depending on the organism to be administered, the sex of the person being administered It is set as appropriate according to conditions such as weight, age and the like. As described above, the anti-obesity agent of the present invention can provide an obesity-suppressing effect even in animals such as pets and livestock, and therefore can be provided as a form associated with pet food and feed. it can.

  Next, examples will be described. However, the present invention is not limited to these examples.

[Pinitol Efficacy Test Using High-Fat Diet Mice]
C57BL / 6 Jcl male mice (4 suitable age) were purchased from Japan SLC as mice, and the efficacy of pinitol was confirmed when fed with a basic diet freely and fed with a high fat diet freely A test was conducted. As the basic food, AIN-93 powder feed (manufactured by Nippon Agricultural Corporation) was used. In addition, per 100g of the basic food, casein 14g, L-cysteine 0.2g, corn starch 46.5g, dextrin 15.5g, sucrose 10g, soybean oil 4g, cellulose 5g, mineral mix 3.5g, vitamin mix 1g, bitartrate Contains 0.3 g of choline and 0.0008 g of tert-butylhydroquinone. Moreover, as said high fat meal, what reduced the amount of corn starch per 100g of said basic meal 30g, and added 30g of lard instead was used.

  First, the purchased mice were divided into 6 groups (12 mice per group), the first to third groups were bred based on the basic diet, and the fourth to sixth groups were bred based on the high fat diet. That is, in the first to third groups, the control group, which is the first group, is bred with only the basic diet, and the myo-inositol administration group, which is the second group, is 0 in the basic diet. The feed was mixed with 2% by weight of the feed, and the third group of the pinitol administration group was fed with a feed containing 0.2% by weight of pinitol (Pinitol extracted from locust bean) in the basic diet. In groups 4-6, the control group, which is the fourth group, is bred only with a high fat diet, and the myo-inositol administration group, which is the fifth group, is fed with a high fat diet. Was fed with a feed mixed with 0.2% by weight of a high fat diet. The first group and the fourth group are control examples, the second group and the fifth group are comparative examples, and the third group and the sixth group are examples.

  As described above, mice of each group were bred, and food intake, water intake, and body weight were measured every week, and fasting blood glucose levels were measured every 4 weeks. In addition, a glucose tolerance test (OGTT) was conducted on the 13th week from the start of the breeding. Further, at the end of the 15th week of the test, the whole number was dissected and the tissue weight of each part was measured.

  As a result, the following findings were observed in each group of mice.

  That is, regarding the body weight, no significant difference was observed between the first to third groups reared on the basis of the basic diet even at the 15th week after the start of the rearing. Indicated. On the other hand, between the 4th and 6th groups reared on the basis of a high fat diet, the average body weight was 48 g in the fourth group as the control group at the 15th week after the start of the breeding, whereas myo-inositol was shown. The administration group, group 5, showed an average body weight of 45 g, and the pinitol administration group, group 6, showed an average body weight of 42 g. And from this data, in the comparison with the control group, the fourth group, the pinitol administration group, the sixth group, showed a significant difference with a risk rate of less than 5%.

On the other hand, regarding the above fasting blood glucose level, no significant difference was observed between the first to third groups reared on the basis of the basic diet even at the 12th week of the start of the breeding, and both averaged about 120 mg at the 12th week of the rearing of the breeding. A value of about / dl was shown, and no significant difference was observed. In addition, the AUC (area under the curve) value (integral value) up to the 12th week after the start of breeding with respect to the measured value showed a value of about 17 mg / dl × min × 10 ² , and no significant difference was observed. . On the other hand, among the 4th to 6th groups reared on the basis of the high fat diet, the AUC value up to the 12th week after the start of the breeding averaged 25 mg / dl × min × 10 ² in the fourth group as the control group. On the other hand, the myo-inositol-administered group 5 showed an average of 20 mg / dl × min × 10 ² , and the pinitol-administered group showed an average of 19 mg / dl × min × 10 ² . . From this data, a significant difference was observed between the group 5 as the myo-inositol administration group and the group 6 as the pinitol administration group at a risk rate of less than 5% in comparison with the group 4 as the control group. It was.

On the other hand, regarding the glucose tolerance test, no significant difference was observed between the first to third groups reared based on the basic diet, and the blood glucose level temporarily increased to about 250 mg / dl on average after 180 minutes. The blood glucose level before loading (average of about 140 mg / dl) was restored. And the AUC (area under the curve) value (integral value) with respect to the measured value showed a value of about 25 mg / dl × min × 10 ³ , and no significant difference was recognized. On the other hand, among the 4th to 6th groups raised on the basis of a high fat diet, the AUC value showed an average of 70 mg / dl × min × 10 ³ in the fourth group as the control group, The 5th group that was the myo-inositol administration group showed an average of 50 mg / dl × min × 10 ^3, and the 6th group that was the pinitol administration group showed an average of 45 mg / dl × min × 10 ³ . From this data, a significant difference was observed between the group 5 as the myo-inositol administration group and the group 6 as the pinitol administration group at a risk rate of less than 5% in comparison with the group 4 as the control group. It was.

  Then, at the 15th week after the end of the test, the whole number was dissected and the tissue weight of each part was measured. As a result, when the white adipose tissue weight was compared with the first to third groups, the fourth to sixth groups showed a tendency for the white adipose tissue weight to be high. However, when compared between groups 4-6, the total white adipose tissue weight of group 4 was 24.3 ± 0.9% body weight, whereas the total white adipose tissue weight of group 5 was 26. The total white adipose tissue weight of Group 6 was 19.5 ± 1.9 body weight%. From this data, in comparison with the control group, the fourth group, the pinitol administration group, the sixth group, showed a significant difference with a risk rate of less than 5%. In particular, looking only at the data of subcutaneous fat weight, the subcutaneous fat weight of the fourth group was 13.0 ± 0.8% by weight, whereas the subcutaneous fat weight of the fifth group was 14.6 ± 0.00%. The weight of subcutaneous fat in Group 6 was 9.7 ± 1.1% by weight. As described above, the weight of the subcutaneous fat in the sixth group was remarkably low, which was as low as the weight of the subcutaneous fat in the first to third groups bred based on the basic diet.

  From these results, it was found that when pinitol was ingested at the same time as a high fat diet, the blood glucose level lowering effect and glucose tolerance improvement effect were similar to those in the case of ingesting myo-inositol at the same time as the high fat diet. However, the myo-inositol administration group showed little effect of suppressing body weight gain or suppressing the increase in total white adipose tissue weight, particularly subcutaneous fat weight, whereas the pinitol administration group had these effects. Since the difference was recognized, it can be seen that these obesity-inhibiting effects are not immediately related to the blood glucose level lowering effect or the glucose tolerance abnormality improving effect. And it was newly found from the above test that pinitol has an excellent anti-obesity activity and is particularly excellent in the inhibitory effect on the increase in subcutaneous fat weight.

  The soybean raw grain was immersed in 3 times the amount of water for 8 hours. The soaked soybeans were taken out and boiled for 3 hours with an equal amount of water. The boiled soybeans obtained were soaked in an equal volume of seasoning liquid containing 3% by weight of pinitol for 8 hours to infiltrate the pinitol into the soybeans to obtain boiled beans containing 1% by weight of pinitol. Since this boiled bean contains pinitol as an active ingredient, it has anti-obesity activity from the test results obtained in Example 1 above.

  Two times the amount of hot water (95 ° C.) was added to the water soaked soybeans, and soy milk was prepared using a homogenizer. The pinitol content in the obtained soymilk was 0.05% by weight. Therefore, pinitol was added to the soymilk so that the final content was 2% by weight to obtain pinitol-enriched soymilk. Since this soymilk contains pinitol as an active ingredient, it has anti-obesity activity based on the test results obtained in Example 1 above.

  Sucrose, 0.1% citric acid, and 0.1% pinitol were added to water to a final concentration of 5% by weight, and an appropriate amount of citrus flavor was added to obtain a soft drink. Since this soft drink contains pinitol as an active ingredient, it has anti-obesity activity from the test results obtained in Example 1 above.

  Raw grain soybeans were put in twice the amount of hot water (95-100 ° C.), crushed with a homogenizer, and filtered through a cloth to obtain soy milk. Since the soymilk had a pinitol content of 0.1% by weight, 0.4% by weight of pinitol was added to prepare soymilk containing 0.5% by weight of pinitol. Pinitol-enriched tofu was obtained by adding 0.4% by weight of magnesium chloride to the soy milk. Since this tofu contains pinitol as an active ingredient, it has anti-obesity activity based on the test results obtained in Example 1 above.

  Appropriate amounts of spices such as 1/10 volume of pinitol containing 10% by weight of pinitol soy extract and mint were added to the gum base, and calcium carbonate was added and kneaded to a content of 1% by weight. This was formed into a plate shape to obtain a 10 g plate gum. Since this board gum contains pinitol as an active ingredient, it has anti-obesity activity from the test results obtained in Example 1 above.

  The anti-obesity agent of the present invention contains pinitol as an active ingredient, and can suppress obesity and effectively suppress the deposition of subcutaneous fat without substantially showing any side effects. It is useful above. Moreover, since the food / beverage products containing the said anti-obesity agent can be applied to all food / beverage products, they are industrially useful also in the meaning which gives a functional added value to food / beverage products.

Claims (4)

  An anti-obesity agent comprising pinitol as an active ingredient.   The antiobesity agent according to claim 1, wherein the pinitol content is set in the range of 0.01 to 100% by weight.   The antiobesity agent according to claim 1 or 2, wherein the daily intake of pinitol is set in a range of 10 to 1200 mg.   A food or drink comprising the anti-obesity agent according to any one of claims 1 to 3.